Apr 06,2023

Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time

DexCom, Inc. today announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023. Management will hold a conference call to review the company's first quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 04,2023

Digital Health Product Leader, Eitan Shay, Joins Dario as Chief Product Officer

DarioHealth Corp announced today that digital health veteran, Eitan Shay, is joining the Company in the newly created position of Chief Product Officer. Dario also announced today that digital and business transformation leader, Arnaud Robert, has joined as Strategic Advisor to Erez Raphael, Dario's Chief Executive Officer.

View Analyst & Ambassador Comments
Go to original news
Apr 03,2023

Wellth raises $20M for health app with financial rewards

Wellth, a digital health startup that offers small financial rewards for completing health-related tasks, scooped up $20 million in Series B funding. Wellth works with insurers, providers and employers to offer an app that reminds users about daily health behaviors, like taking medications or monitoring blood glucose. When patients take a photo confirming they've completed tasks, they receive small financial incentives. The company includes services for mental health concerns, cardiovascular disease, heart failure, diabetes, cancer, chronic kidney disease and COPD or asthma.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Apr 03,2023

ABBOTT ISSUES SAFETY NOTIFICATION FOR FREESTYLE LIBRE® FAMILY OF READERS IN THE U.S.

Abbott initiated a voluntary medical device correction in February to emphasize instructions for its FreeStyle Libre®, FreeStyle Libre® 14 day and FreeStyle Libre® 2 Readers in the United States due to a limited number of reports worldwide from users over several years that their reader’s lithium-ion battery swelled, infrequently overheated or, in very rare cases, sparked or caught fire.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 02,2023

An Integrated Digital Health Care Platform for Diabetes Management With AI-Based Dietary Management: 48-Week Results From a Randomized Controlled Trial

Researchers investigated the efficacy of an integrated digital health care platform with artificial intelligence (AI)–based dietary management in adults with type 2 diabetes (T2D). In this 48-week, open-label, randomized, multicenter clinical trial, overweight or obese adults with T2D were randomly assigned to one of three groups in a 1:1:1 ratio: group A received routine diabetes care; group B used the digital integrated health care platform by themselves; and group C used the platform with feedback from medical staff and intermittently applied personal continuous glucose monitoring. The decreases in HbA1c from baseline to 24 and 48 weeks in group B and group C were significantly larger than those in group A. Among adults with T2D, use of an integrated digital health care platform with AI-driven dietary management resulted in better glycemia and more weight loss.

CLINICAL STUDY

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 31,2023

Smart Meter announces free program to reduce diabetes care costs

Smart Meter today announced its iGlucose Challenge to healthcare payors and providers in the U.S. to improve care costs for people with diabetes. Tampa, Florida-based Smart Meter aims to reduce the cost of care and lower A1C for people managing diabetes. The company, which provides remote patient monitoring solutions, offers this as a no-risk, performance-based […]

View Analyst & Ambassador Comments
Go to original news
Mar 31,2023

Mallya Cap data integrates with Health2Sync diabetes care app

Taiwanese startup Health2Sync has announced the integration of Biocorp's Mallya cap with its mobile diabetes management app. Mallya, which attaches directly to the NovoNordisk FlexTouch insulin pen, can now automatically collect and send data on injection dosage, date, and time wirelessly to the Health2Sync app in real time. Mallya data integration is now available to about 350,000 Health2Sync users in Japan.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 30,2023

Insulet to Announce First Quarter 2023 Financial Results on May 4, 2023

Insulet Corporation announced plans to release its financial results for the first quarter of 2023 on May 4, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Mar 30,2023

Dr. Nicolas Meyer succeeds Dr. Beat Maurer on the Executive Board

Ypsomed announces a change in its Executive Board. After more than thirty years with Ypsomed and formerly Disetronic, Dr Beat Maurer will retire as Chief Legal Officer (CLO) on 31 March 2023. He will be succeeded by Dr Nicolas Meyer, who will take up the position as CLO at Ypsomed on 01 May 2023.

View Analyst & Ambassador Comments
Go to original news
Mar 30,2023

Better Therapeutics hopes FDA nod for diabetes digital therapeutic comes in 2023

Better Therapeutics shares ticked up on fourth-quarter results and projections for its flagship product in 2023. The company’s quarterly results come on the heels of a 35% headcount reduction. Better Therapeutics said the headcount cut comes as part of a cost reduction initiative. It aims to improve its cash runway and “focus on the long-term success of the company” which develops a range of digital therapeutics, including BT-001 for treating type 2 diabetes. In the quarter, the San Francisco-based digital therapeutics developer posted losses of $8.8 million. That amounts to 37¢ per share. t marks a year-over-year improvement on the bottom line from losses of $13.9 million in Q4 2021.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES